The management of Babesia, amoeba and other zoonotic diseases provoked by protozoa

References

• Fitri LE, Candradikusuma D, Setia YD, et al. Diagnostic methods of common intestinal protozoa: current and future immunological and molecular methods. Trop Med Infect Dis. 2022 Sep 21;7(10):253. DOI:10.3390/tropicalmed7100253. PMID: 36287994; PMCID: PMC9606991.
   PubMedGoogle Scholar
• RG Y. Protozoa: structure, Classification, Growth, and Development. In: Baron S, editor. Medical Microbiology. 4th ed. Galveston (TX): University of Texas Medical Branch at Galveston; 1996. Chapter 77. PMID: 21413323.
   Google Scholar
• Vermelho AB, Supuran CT. In: Antiprotozoal Drug Development and Delivery. 2022. Springer Nature: Cham. (Topics in Medicinal Chemistry).
   Google Scholar
• E S-M. Toxoplasmosis: stages of the protozoan life cycle and risk assessment in humans and animals for an enhanced awareness and an improved socio-economic status. Saudi J Biol Sci. 2021 Jan;28(1):962–969.
   PubMed Web of Science ®Google Scholar
• Esch KJ, Petersen CA. Transmission and epidemiology of zoonotic protozoal diseases of companion animals. Clin Microbiol Rev. 2013 Jan;26(1):58–85.
   PubMed Web of Science ®Google Scholar
• La Hoz RM, Morris MI. Infectious diseases community of practice of the American Society of T. Tissue and blood protozoa including toxoplasmosis, Chagas disease, leishmaniasis, Babesia, Acanthamoeba, Balamuthia, and Naegleria in solid organ transplant recipients- Guidelines from the American society of transplantation infectious diseases community of practice. Clin Transplant. 2019 Sep;33(9):e13546.
   PubMed Web of Science ®Google Scholar
• Rahman MT, Sobur MA, Islam MS, et al. Zoonotic diseases: etiology, impact, and control. Microorganisms. 2020 Sep 12;8(9):1405. DOI:10.3390/microorganisms8091405. PMID: 32932606; PMCID: PMC7563794.
   PubMed Web of Science ®Google Scholar
• Overgaauw PAM, Vinke CM, Hagen M, et al. A one health perspective on the human-companion animal relationship with emphasis on zoonotic aspects. Int J Environ Res Public Health. 2020 May 27;17(11):3789 DOI:10.3390/ijerph17113789. PMID: 32471058; PMCID: PMC7312520.
   PubMed Web of Science ®Google Scholar
• Waked R, Krause PJ. Human Babesiosis. Infect Dis Clin N Am. 2022 Sep;36(3):655–670.
   PubMed Web of Science ®Google Scholar
• Brownstein JS, Holford TR, Fish D. Effect of climate change on lyme disease risk in North America. Ecohealth. 2005 Mar;2(1):38–46.
   PubMedGoogle Scholar
• Allehebi ZO, Khan FM, Robbins M, et al. Lyme disease, Anaplasmosis, and Babesiosis, Atlantic Canada. Emerg Infect Dis. 2022 Jun;28(6):1292–1294.
   PubMed Web of Science ®Google Scholar
• Rojas-Pirela M, Medina L, Rojas MV, et al. Congenital transmission of apicomplexan parasites: a review. Front Microbiol . 2021 Sep 29;12:751648.DOI:0.3389/fmicb.2021.751648. PMID: 34659187; PMCID: PMC8519608.
   Web of Science ®Google Scholar
• Gray J, Zintl A, Hildebrandt A, et al. Zoonotic babesiosis: overview of the disease and novel aspects of pathogen identity. Ticks Tick Borne Dis. 2010 Mar;1(1):3–10.
   PubMed Web of Science ®Google Scholar
• Leiby DA. Transfusion-transmitted Babesia spp.: bull’s-eye on Babesia microti. Clin Microbiol Rev. 2011 Jan;24(1):14–28.
   PubMed Web of Science ®Google Scholar
• Bloch EM, Day JR, Krause PJ, et al. Epidemiology of Hospitalized Patients with Babesiosis, United States, 2010-2016. Emerg Infect Dis. 2022 ;28(2):354–362. DOI:10.3201/eid2802.210213. PMID: 35076004; PMCID: PMC8798708.
   PubMed Web of Science ®Google Scholar
• Renard I, Ben Mamoun C. Treatment of human babesiosis: then and now. Pathogens. 2021 Sep;10(9):1120. DOI:10.3390/pathogens10091120. PMID: 34578153; PMCID: PMC8469882.
   PubMed Web of Science ®Google Scholar
• Jacobsen L, Husen P, Solov’yov IA. Inhibition mechanism of antimalarial drugs targeting the cytochrome bc(1) complex. J Chem Inf Model. 2021 Mar 22;61(3):1334–1345.
   PubMed Web of Science ®Google Scholar
• Dahl EL, Rosenthal PJ. Multiple antibiotics exert delayed effects against the Plasmodium falciparum anicoplast. Antimicrob Agents Ch. 2007 Oct;51(10):3485–3490.
   PubMed Web of Science ®Google Scholar
• Pfefferkorn ER, Borotz SE. Comparison of mutants of Toxoplasma gondii selected for resistance to azithromycin, spiramycin, or clindamycin. Antimicrob Agents Chemother. 1994 Jan;38(1):31–37.
   PubMed Web of Science ®Google Scholar
• Tang YQ, Ye Q, Huang H, et al. An overview of available antimalarials: discovery, mode of action and drug resistance. Curr Mol Med. 2020;20(8):583–592.
   PubMed Web of Science ®Google Scholar
• Punihaole D, Workman RJ, Upadhyay S, et al. New Insights into quinine-DNA binding using raman spectroscopy and molecular dynamics simulations. J Phys Chem B. 2018 Nov 1;122(43):9840–9851.
   PubMed Web of Science ®Google Scholar
• Yao JM, Zhang HB, Liu CS, et al. Inhibitory effects of 19 antiprotozoal drugs and antibiotics on Babesia microti infection in BALB/c mice. J Infect Dev Countr. 2015 Sep;9(9):1004–1010.
   PubMed Web of Science ®Google Scholar
• Batiha GE, Beshbishy AM, Tayebwa DS, et al. Inhibitory effects of Syzygium aromaticum and Camellia sinensis methanolic extracts on the growth of Babesia and Theileria parasites. Ticks Tick-Borne Dis. 2019 Aug;10(5):949–958.
   PubMed Web of Science ®Google Scholar
• Batiha GE, Beshbishy AM, Guswanto A, et al. Phytochemical characterization and chemotherapeutic potential of cinnamomum verum extracts on the multiplication of protozoan parasites in vitro and in vivo. Molecules. 2020 Feb 24;25(4):996. DOI:10.3390/molecules25040996. PMID: 32102270; PMCID: PMC7070835.
   PubMed Web of Science ®Google Scholar
• Rizk MA, El-Sayed SA, AbouLaila M, et al. Large-scale drug screening against babesia divergens parasite using a fluorescence-based high-throughput screening assay. Am J Trop Med Hyg. 2017 Nov;95(5):409.
   Web of Science ®Google Scholar
• Batiha GE, Beshbishy AM, Tayebwa DS, et al. The effects of trans-chalcone and chalcone 4 hydrate on the growth of Babesia and Theileria. PLoS Neglect Trop D. 2019 May;13(5):e0007030. DOI:10.1371/journal.pntd.0007030. PMID: 31125333; PMCID: PMC6534319.
   PubMed Web of Science ®Google Scholar
• Batiha GE, Beshbishy AM, Adeyemi OS, et al. Safety and efficacy of hydroxyurea and eflornithine against most blood parasites Babesia and Theileria. PLoS ONE. 2020 Feb 13;15(2):e022899. DOI:10.1371/journal.pone.0228996. PMID: 32053698; PMCID: PMC7018007.
   Web of Science ®Google Scholar
• Omar MA, Salama A, Elsify A, et al. Evaluation of in vitro inhibitory effect of, enoxacin on Babesia and Theileria parasites. Exp Parasitol. 2016 Feb;161:62–67.
   PubMed Web of Science ®Google Scholar
• van Schalkwyk DA, Riscoe MK, Pou S, et al. Novel endochin-like quinolones exhibit potent in vitro activity against plasmodium knowlesi but do not synergize with proguanil. Antimicrob Agents Chemother. 2020 Apr 21;64(5) :e02549–19. DOI:10.1128/AAC.02549-19. PMID: 32094134; PMCID: PMC7179610.
   PubMed Web of Science ®Google Scholar
• Carvalho LJM, Tuvshintulga B, Nugraha AB, et al. Activities of artesunate-based combinations and tafenoquine against Babesia bovis in vitro and Babesia microti in vivo. Parasites Vectors. 2020 Jul 20;13(1):362.
   PubMed Web of Science ®Google Scholar
• Tuvshintulga B, AbouLaila M, Davaasuren B, et al. Clofazimine Inhibits the Growth of Babesia and Theileria Parasites in vitro and in vivo. Antimicrob Agents Chemother. 2016 May;60(5):2739–2746.
   PubMed Web of Science ®Google Scholar
• Stickles AM, de Almeida MJ, Morrisey JM, et al. Subtle Changes in Endochin-Like Quinolone Structure Alter the Site of Inhibition within the Cytochrome bc(1) Complex of Plasmodium falciparum. Antimicrob Agents Ch. 2015 Apr;59(4):1977–1982.
   PubMed Web of Science ®Google Scholar
• Winter R, Kelly JX, Smilkstein MJ, et al. Optimization of endochin-like quinolones for antimalarial activity. Exp Parasitol. 2011 Feb;127(2):545–551.
   PubMed Web of Science ®Google Scholar
• Bhanot P, Parveen N. Investigating disease severity in an animal model of concurrent babesiosis and Lyme disease. Int J Parasitol. 2019 Feb;49(2):145–151.
   PubMed Web of Science ®Google Scholar
• Guillen N. Pathogenicity and virulence of Entamoeba histolytica, the agent of amoebiasis. Virulence. 2023 Dec;14(1):2158656.
   PubMed Web of Science ®Google Scholar
• Gupta S, Smith L, Diakiw A. Amebiasis and Amebic Liver Abscess in Children. Pediatr Clin N Am. 2022 Feb;69(1):79–97.
   PubMed Web of Science ®Google Scholar
• Naous A, Naja Z, Zaatari N, et al. Intestinal amebiasis: a concerning cause of acute gastroenteritis among hospitalized Lebanese children. N Am J Med Sci. 2013 Dec;5(12):689–698.
   PubMedGoogle Scholar
• Shirley DAT, Watanabe K, Moonah S. Significance of amebiasis: 10 reasons why neglecting amebiasis might come back to bite us in the gut. PLoS Neglect Trop D. 2019 Nov;13(11):e0007744. DOI:10.1371/journal.pntd.0007744. PMID: 31725715; PMCID: PMC6855409.
   PubMed Web of Science ®Google Scholar
• Mori Y, Shimizu S, Nishiguchi Y, et al. A clinical study of fulminant amebic colitis. Nihon Shokakibyo Gakkai Zasshi. 2015 May;112(5):871–879.
   PubMedGoogle Scholar
• Haque R, Huston CD, Hughes M, et al. Amebiasis. New Engl J Med. 2003 Apr 17;348(16):1565–1573.
   PubMed Web of Science ®Google Scholar
• Hung CC, Chang SY, Ji DD. Entamoeba histolytica infection in men who have sex with men. Lancet Infect Dis. 2012 Sep;12(9):729–736.
   PubMed Web of Science ®Google Scholar
• Kantor M, Abrantes A, Estevez A, et al. Entamoeba Histolytica: updates in clinical manifestation, pathogenesis, and vaccine development. Can J Gastroenterol. Dec 2018;2018:4601420. DOI:10.1155/2018/4601420. PMID: 30631758; PMCID: PMC6304615.
   Web of Science ®Google Scholar
• Shirley DAT, Farr L, Watanabe K, et al. A review of the global burden, new diagnostics, and current therapeutics for amebiasis. Open Forum Infect Di. 2018 Jul;5(7):ofy161. DOI:10.1093/ofid/ofy161. PMID: 30046644; PMCID: PMC6055529.
   PubMed Web of Science ®Google Scholar
• Ralston KS, Solga MD, Mackey-Lawrence NM, et al. Trogocytosis by Entamoeba histolytica contributes to cell killing and tissue invasion. Nature. 2014 Apr 24;508(7497):526±.
   PubMed Web of Science ®Google Scholar
• Yu Y, Chadee K. Entamoeba histolytica stimulates interleukin 8 from human colonic epithelial cells without parasite-enterocyte contact. Gastroenterology. 1997 May;112(5):1536–1547.
   PubMed Web of Science ®Google Scholar
• Moonah SN, Jiang NM, Petri WA. HosT immune response to intestinal amebiasis. PLOS Pathog. 2013 Aug;9(8):e1003489. DOI:10.1371/journal.ppat.1003489. Epub 2013 Aug 22. PMID: 23990778; PMCID: PMC3749964.
   PubMed Web of Science ®Google Scholar
• Gonzales MLM, Dans LF, Sio-Aguilar J. Antiamoebic drugs for treating amoebic colitis. Cochrane Db Syst Rev. 2019 Jan 9;1(1):CD006085. DOI:10.1002/14651858.CD006085.pub3. PMID: 30624763; PMCID: PMC6326239.
   PubMed Web of Science ®Google Scholar
• Redulla R. Antiamoebic drugs for treating amoebic colitis: a Cochrane review summary. Int J Nurs Stud. 2021 Jun;118:103650. DOI:10.1016/j.ijnurstu.2020.103650. Epub 2020 May 20. PMID: 33189330.
   Web of Science ®Google Scholar
• Abdallah A, Kordy MI, Saif M. Paromomycin in the treatment of acute intestinal amoebiasis. J Egypt Med Assoc. 1960;43:915–922.
   PubMedGoogle Scholar
• Courtney KO, Thompson PE, Hodgkinson R, et al. Paromomycin as a therapeutic substance for intestinal amoebiasis and bacterial enteritis. Ann Biochem Exp Med. 1960;20(Suppl):449–456.
   Google Scholar
• Wagner ED, Burnett HS. Paromomycin in the treatment of amoebiasis in Nyasaland. Trans R Soc Trop Med Hyg. 1961 Sep;55:428–430.
   PubMedGoogle Scholar
• Rossignol JF, Kabil SM, El-Gohary Y, et al. Nitazoxanide in the treatment of amoebiasis. T Roy Soc Trop Med H. 2007 Oct;101(10):1025–1031.
   PubMed Web of Science ®Google Scholar
• Capparelli EV, Bricker-Ford R, Rogers MJ, et al. Phase I clinical trial results of auranofin, a novel antiparasitic agent. Antimicrob Agents Ch. 2017 Dec 27;61(1):e01947-16. DOI:10.1128/AAC.01947-16. PMID: 27821451; PMCID: PMC5192119.
   Web of Science ®Google Scholar
• Deloer S, Nakamura R, Mi-Ichi F, et al. Mouse models of amoebiasis and culture methods of amoeba. Parasitol Int. 2016 Oct;65(5 Pt B):520–525.
   PubMed Web of Science ®Google Scholar
• Becker S, Hoffman P, Houpt ER. Efficacy of antiamebic drugs in a mouse model. Am J Trop Med Hyg. 2011 Apr;84(4):581–586.
   PubMed Web of Science ®Google Scholar
• Robert-Gangneux F, Darde ML. Epidemiology of and diagnostic strategies for toxoplasmosis. Clin Microbiol Rev. 2012 Apr;25(2):264–296.
   PubMed Web of Science ®Google Scholar
• Delgado ILS, Z S, Santos D, et al. The Apicomplexan Parasite Toxoplasma gondii. Encyclopedia. 2022;2:189–211.
   Google Scholar
• Dubey JP, Lindsay DS, Speer CA. Structures of Toxoplasma gondii tachyzoites, bradyzoites, and sporozoites and biology and development of tissue cysts. Clin Microbiol Rev. 1998 Apr;11(2):267–299.
   PubMed Web of Science ®Google Scholar
• Lima TS, Lodoen MB. Mechanisms of Human Innate Immune Evasion by Toxoplasma gondii. Front Cell Infect Microbiol. 2019;9:103.
   PubMed Web of Science ®Google Scholar
• Chulanetra M, Chaicumpa W. Revisiting the mechanisms of immune evasion employed by human parasites. Front Cell Infect Microbiol. 2021;11:702125.
   PubMed Web of Science ®Google Scholar
• Fox BA, Guevara RB, Rommereim LM, et al. Toxoplasma gondii parasitophorous vacuole membrane-associated dense granule proteins orchestrate chronic infection and GRA12 underpins resistance to host gamma interferon. MBio. 2019 Jul 2;10:(4):e00589-19. DOI:10.1128/mBio.00589-19. PMID: 31266861; PMCID: PMC6606796.
   Web of Science ®Google Scholar
• Uddin A, Hossain D, Ahsan MI, et al. Review on diagnosis and molecular characterization of Toxoplasma gondii in humans and animals. Trop Biomed. 2021 Dec 1;38(4):511–539.
   PubMed Web of Science ®Google Scholar
• Hajj RE, Tawk L, Itani S, et al. Toxoplasmosis: current and emerging parasite druggable targets. Microorganisms. 2021 Dec;9(12):2531. DOI:10.3390/microorganisms9122531. PMID: 34946133; PMCID: PMC8707595.
   PubMed Web of Science ®Google Scholar
• Spalenka J, Escotte-Binet S, Bakiri A, et al. Discovery of new inhibitors of toxoplasma gondii via the pathogen box. Antimicrob Agents Ch. 2018 Jan;62(2):e01640-17. DOI:10.1128/AAC.01640-17. PMID: 29133550; PMCID: PMC5786798.
   PubMed Web of Science ®Google Scholar
• Konstantinovic N. Treatment of toxoplasmosis: current options and future perspectives. Food Waterb Parasit. 2019 [2020 Dec; 21];15:e00036.
   PubMedGoogle Scholar
• Konstantinovic N, Guegan H, Stajner T, et al. Treatment of toxoplasmosis: current options and future perspectives. Food Waterb Parasit. 2019 Apr;1:e00036. DOI:10.1016/j.fawpar.2019.e00036. Erratum in: Food Waterborne Parasitol. 2020 Dec 15;21:e00105. PMID: 32095610; PMCID: PMC7033996.
   Google Scholar
• Robert-Gangneux F. It is not only the cat that did it: how to prevent and treat congenital toxoplasmosis. J Infection. 2014 Jan;68:S125–133.
   PubMed Web of Science ®Google Scholar
• Torre D, Casari S, Speranza F, et al. Randomized trial of trimethoprim-sulfamethoxazole versus pyrimethamine-sulfadiazine for therapy of toxoplasmic encephalitis in patients with AIDS. Italian Collaborative Study Group. Antimicrob Agents Chemother. 1998 Jun;42(6):1346–1349.
   PubMed Web of Science ®Google Scholar
• Valentini P, Annunziata ML, Angelone DF, et al. Role of spiramycin/cotrimoxazole association in the mother-to-child transmission of toxoplasmosis infection in pregnancy (vol 28, pg 298, 2009). Eur J Clin Microbiol. 2009 Jul;28(7):879.
   Google Scholar
• Djurkovic-Djakovic O, Nikolic T, Robert-Gangneux F, et al. Synergistic effect of clindamycin and atovaquone in acute murine toxoplasmosis. Antimicrob Agents Ch. 1999 Sep;43(9):2240–2244.
   PubMed Web of Science ®Google Scholar
• Heath RJ, Rock CO. Enoyl-Acyl carrier protein reductase (Fabi) plays a determinant role in completing cycles of fatty-acid elongation in Escherichia-coli. J Biol Chem. 1995 Nov 3;270(44):26538–26542.
   PubMed Web of Science ®Google Scholar
• Ling Y, Li ZH, Miranda K, et al. The Farnesyl-diphosphate/geranylgeranyl-diphosphate synthase of Toxoplasma gondii is a bifunctional enzyme and a molecular target of bisphosphonates. J Biol Chem. 2007 Oct 19;282(42):30804–30816.
   PubMed Web of Science ®Google Scholar
• Scheele S, Geiger JA, DeRocher AE, et al. Toxoplasma calcium-dependent protein kinase 1 inhibitors: probing activity and resistance using cellular thermal shift assays. Antimicrob Agents Ch. 2018 May 25;62(6):e00051-18. DOI:10.1128/AAC.00051-18. PMID: 29555627; PMCID: PMC5971589.
   PubMed Web of Science ®Google Scholar
• Montazeri M, Mehrzadi S, Sharif M, et al. Activities of anti-Toxoplasma drugs and compounds against tissue cysts in the last three decades (1987 to 2017), a systematic review. Parasitol Res. 2018 Oct;117(10):3045–3057.
   PubMed Web of Science ®Google Scholar
• Bonardi A, Parkkila S, Supuran CT. Inhibition studies of the protozoan alpha-carbonic anhydrase from Trypanosoma cruzi with phenols. J Enzyme Inhib Med Chem. 2022 Dec;37(1):2417–2422.
   PubMed Web of Science ®Google Scholar
• Capasso C, Supuran CT. Anti-infective carbonic anhydrase inhibitors: a patent and literature review. Expert Opin Ther Pat. 2013;23(6):693–704.
   PubMed Web of Science ®Google Scholar
• Supuran CT. Emerging role of carbonic anhydrase inhibitors. Clin Sci (Lond). 2021 May 28;135(10):1233–1249.
   PubMed Web of Science ®Google Scholar
• Winum JY, Supuran CT. Recent advances in the discovery of zinc-binding motifs for the development of carbonic anhydrase inhibitors. J Enzyme Inhib Med Chem. 2015 Apr;30(2):321–324.
   PubMed Web of Science ®Google Scholar
• Emameh RZ, Barker H, Tolvanen MEE, et al.Bioinformatic analysis of beta carbonic anhydrase sequences from protozoans and metazoans.Parasite Vector.72014 Jan 21;7:38. DOI:10.1186/1756-3305-7-38. PMID: 24447594; PMCID: PMC3907363.
   Web of Science ®Google Scholar
• Parkkila AK, Scarim AL, Parkkila S, et al. Expression of carbonic anhydrase V in pancreatic beta cells suggests role for mitochondrial carbonic anhydrase in insulin secretion. J Biol Chem. 1998 Sep 18;273(38):24620–24623.
   PubMed Web of Science ®Google Scholar
• Ramakrishnan S, Serricchio M, Striepen B, et al. Lipid synthesis in protozoan parasites: a comparison between kinetoplastids and apicomplexans. Prog Lipid Res. 2013 Oct;52(4):488–512.
   PubMed Web of Science ®Google Scholar
• Mansoldo FRP, Carta F, Angeli A, et al.Chagas disease: perspectives on the past and present and challenges in drug discoveryMolecules. 2020Nov 23;2522:5483. DOI:10.3390/molecules25225483. PMID: 33238613; PMCID: PMC7700143.
   PubMed Web of Science ®Google Scholar
• Britto CC. Revisiting Chagas’ disease diagnostic strategies in light of different scenarios of Trypanosoma cruzi infection. Mem I Oswaldo Cruz. 2022 May 23;117:e210444chgsb. DOI:10.1590/0074-02760210444chgsb. PMID: 35613158; PMCID: PMC9164940.
   Web of Science ®Google Scholar
• Lidani KCF, Andrade FA, Bavia L, et al.Chagas disease: from discovery to a worldwide health problem.Front Public Health. 2019 Jul 2;7:166. DOI:10.3389/fpubh.2019.00166. PMID: 31312626; PMCID: PMC6614205.
   Web of Science ®Google Scholar
• Beatty NL, Forsyth CJ, Burkett-Cadena N, et al. Our current understanding of chagas disease and trypanosoma cruzi infection in the state of Florida - an update on research in this region of the USA. Curr Trop Med Rep. 2022 Sep 20;9:150–159. DOI:10.1007/s40475-022-00261-w
   Google Scholar
• 2020: a crucial year for neglected tropical diseases. The Lancet. 2019 Dec 14;394(10215):2126. DOI:10.1016/S0140-6736(19)33070-3. PMID: 31839179.
   Web of Science ®Google Scholar
• Ramalho E, Albuquerque J, Cristino C, et al. Congenital and blood transfusion transmission of chagas disease: a framework using mathematical modeling. Complexity. 2018 Nov 1[cited 2023 Apr 21]; Volume 2018. Available from: https://hdl.handle.net/2117/12731
   Web of Science ®Google Scholar
• Roca C, Malaga-Machaca ES, Verastegui MR, et al. IgG subclasses and congenital transmission of chagas disease. Am J Trop Med Hyg. 2021 Nov;105(5):1187–1192.
   PubMed Web of Science ®Google Scholar
• Kingwell K. New therapeutic candidate for Chagas disease. Nat Rev Drug Discov. 2022 Nov;21(11):796.
   PubMed Web of Science ®Google Scholar
• Caldas IS, Santos EG, Novaes RD. An evaluation of benznidazole as a Chagas disease therapeutic. Expert Opin Pharmaco. 2019 Oct 13;20(15):1797–1807.
   PubMed Web of Science ®Google Scholar
• Teixeira ARL, Hecht MM, Guimaro MC, et al. Pathogenesis of Chagas’ disease: parasite persistence and autoimmunity. Clinical Microbiology Reviews. 2011 Jul;24(3):592–630.
   PubMed Web of Science ®Google Scholar
• Filardy AA, Guimaraes-Pinto K, Nunes MP, et al.Human Kinetoplastid Protozoan infections: where are we going next?Front Immunol. 92018 Jul 25;9:1493. DOI:10.3389/fimmu.2018.01493. PMID: 30090098; PMCID: PMC6069677.
   Web of Science ®Google Scholar
• Echeverria LE, Morillo CA. American Trypanosomiasis (Chagas Disease). Infect Dis Clin N Am. 2019 Mar;33(1):119±.
   PubMed Web of Science ®Google Scholar
• Ley V, Robbins ES, Nussenzweig V, et al. The exit of Trypanosoma cruzi from the phagosome is inhibited by raising the pH of acidic compartments. J Exp Med. 1990 Feb 1;171(2):401–413.
   PubMed Web of Science ®Google Scholar
• Dunn N, Wang S, Adigun R. African Trypanosomiasis. In: StatPearls [Internet]. Treasure Island (FL): StarPearls Publishing; 20222023 Jan–. PMID: 30137864.
   Google Scholar
• Caradonna KL, Burleigh BA. Mechanisms of host cell invasion by Trypanosoma cruzi. Adv Parasitol. 2011;76:33–61.
   PubMed Web of Science ®Google Scholar
• Luquetti AO, Schmunis GA. American trypanosomiasis Chagas disease: one hundred years of research. 2nd. Elsevier; 2017687–730. DOI:10.1016/B978-0-12-801029-7.00030-7. ISBN 9780128010297.
   Google Scholar
• Urbina JA. Ergosterol biosynthesis and drug development for Chagas disease. Mem I Oswaldo Cruz. 2009 Jul;104:311–318.
   PubMed Web of Science ®Google Scholar
• Villalta F, Dobish MC, Nde PN, et al. VNI cures acute and chronic experimental chagas disease. J Infect Dis. 2013 Aug 1;208(3):504–511.
   PubMed Web of Science ®Google Scholar
• Torrico F, Gascon J, Ortiz L, et al. Treatment of adult chronic indeterminate Chagas disease with benznidazole and three E1224 dosing regimens: a proof-of-concept, randomised, placebo-controlled trial. Lancet Infect Dis. 2018 Apr;18(4):419–430.
   PubMed Web of Science ®Google Scholar
• Urbina JA. The long road towards a safe and effective treatment of chronic Chagas disease. Lancet Infect Dis. 2018 Apr;18(4):363–365.
   PubMed Web of Science ®Google Scholar
• Guedes-da-Silva FH, Batista DGJ, Da Silva CF, et al. Antitrypanosomal Activity of Sterol 14 alpha-Demethylase (CYP51) inhibitors vni and vfv in the swiss mouse models of chagas disease induced by the trypanosoma cruzi Y strain. Antimicrob Agents Ch. 2017 Mar 24;61(4):e02098-16. DOI: 10.1128/AAC.02098-16. PMID: 28167559; PMCID: PMC5365685.
   PubMed Web of Science ®Google Scholar
• Friggeri L, Hargrove TY, Rachakonda G, et al. Structural basis for rational design of inhibitors targeting trypanosoma cruzi sterol 14 alpha-demethylase: two regions of the enzyme molecule potentiate its inhibition. J Med Chem. 2014 Aug 14;57(15):6704–6717.
   PubMed Web of Science ®Google Scholar
• Konkle ME, Hargrove TY, Kleshchenko YY, et al. Indomethacin amides as a novel molecular scaffold for targeting trypanosoma cruzi sterol 14 alpha-demethylase. J Med Chem. 2009 May 14;52(9):2846–2853.
   PubMed Web of Science ®Google Scholar
• Lepesheva GI, Villalta F, Waterman MR. Targeting Trypanosoma cruzi Sterol 14 alpha-Demethylase (CYP51). Adv Parasit. 2011;75:65–87.
   PubMed Web of Science ®Google Scholar
• Bonardi A, Vermelho AB, Cardoso VD, et al. N-Nitrosulfonamides as carbonic anhydrase inhibitors: a promising chemotype for targeting chagas disease and leishmaniasis. ACS Med Chem Lett. 2019 Apr;10(4):413–418.
   PubMed Web of Science ®Google Scholar
• Nocentini A, Cadoni R, Dumy P, et al. Carbonic anhydrases from Trypanosoma cruzi and Leishmania donovani chagasi are inhibited by benzoxaboroles. J Enzym Inhib Med Ch. 2017 Dec 27;33(1):286–289.
   PubMed Web of Science ®Google Scholar
• Supuran CT. Inhibition of carbonic anhydrase from Trypanosoma cruzi for the management of Chagas disease: an underexplored therapeutic opportunity. Future Med Chem. 2016;8(3):311–324.
   PubMed Web of Science ®Google Scholar
• Syrjanen L, Vermelho AB, Rodrigues ID, et al. Cloning, characterization, and inhibition studies of a beta-carbonic anhydrase from leishmania donovani chagasi, the protozoan parasite responsible for leishmaniasis. J Med Chem. 2013 Sep 26;56(18):7372–7381.
   PubMed Web of Science ®Google Scholar
• Nocentini A, Supuran CT. Advances in the structural annotation of human carbonic anhydrases and impact on future drug discovery. Expert Opin Drug Dis. 2019 Nov 2;14(11):1175–1197.
   PubMed Web of Science ®Google Scholar
• D’Ambrosio K, Supuran CT, De Simone G. Are carbonic anhydrases suitable targets to fight protozoan parasitic diseases? Curr Med Chem. 2018;25(39):5266–5278.
   PubMed Web of Science ®Google Scholar
• Supuran CT. Exploring the multiple binding modes of inhibitors to carbonic anhydrases for novel drug discovery. Expert Opin Drug Dis. 2020 Jun 2;15(6):671–686.
   PubMed Web of Science ®Google Scholar
• Bourguignon SC, Cavalcanti DFB, de Souza AMT, et al. Trypanosoma cruzi: insights into naphthoquinone effects on growth and proteinase activity. Exp Parasitol. 2011 Jan;127(1):160–166.
   PubMed Web of Science ®Google Scholar
• Silva JV, Santos SD, Machini MT, et al. Neglected tropical diseases and infectious illnesses: potential targeted peptides employed as hits compounds in drug design. J Drug Target. 2021 Mar 16;29(3):269–283.
   PubMed Web of Science ®Google Scholar
• Salas-Sarduy E, Landaburu LU, Karpiak J, et al. Novel scaffolds for inhibition of Cruzipain identified from high-throughput screening of anti-kinetoplastid chemical boxes. Sci Rep-UK. 2017 [2018 Jun 4];7(8):12073.
   PubMedGoogle Scholar
• Khare S, Nagle AS, Biggart A, et al. Proteasome inhibition for treatment of leishmaniasis, Chagas disease and sleeping sickness. Nature. 2016 Sep 8;537(7619):229±.
   PubMed Web of Science ®Google Scholar
• Zmuda F, Sastry L, Shepherd SM, et al. Identification of novel trypanosoma cruzi proteasome inhibitors using a luminescence-based high-throughput screening assay. Antimicrob Agents Chemother. 2019 Aug;63(9):e00309-19. DOI:10.1128/AAC.00309-19. PMID: 31307977; PMCID: PMC6709497.
   Web of Science ®Google Scholar
• Padilla AM, Wang W, Akama T, et al. Discovery of an orally active benzoxaborole prodrug effective in the treatment of Chagas disease in non-human primates. Nat Microbiol. 2022 Oct;7(10):1536±.
   PubMed Web of Science ®Google Scholar
• Torres-Guerrero E, Quintanilla-Cedillo MR, Ruiz-Esmenjaud J, et al. Leishmaniasis: a review. F1000Res. 2017;6:750.
   PubMedGoogle Scholar
• Ives A, Ronet C, Prevel F, et al. Leishmania RNA virus controls the severity of mucocutaneous leishmaniasis. Science. 2011 Feb 11;331(6018):775–778.
   PubMed Web of Science ®Google Scholar
• Peters NC. In vivo imaging reveals an essential role for neutrophils in leishmaniasis transmitted by sand flies (vol 321, pg 970, 2008). Science. 2008 Dec 12;322(5908):1634.
   PubMed Web of Science ®Google Scholar
• Tesh RB. Control of zoonotic visceral leishmaniasis - is it time to change strategies. Am J Trop Med Hyg. 1995 Mar;52(3):287–292.
   PubMed Web of Science ®Google Scholar
• Reguera RM, Perez-Pertejo Y, Gutierrez-Corbo C, et al. Current and promising novel drug candidates against visceral leishmaniasis. Pure Appl Chem. 2019 Aug;91(8):1385–1404.
   Web of Science ®Google Scholar
• Ben Salah N, Aounallah A, Manaa L, et al. Systemic meglumine antimoniate-induced severe dilated cardiomyopathy. Dermatol Ther. 2022 Dec;35(12):e15896. DOI:10.1111/dth.15896. Epub 2022 Oct 17. PMID: 36193752.
   Web of Science ®Google Scholar
• Salari S, Bamorovat M, Sharifi I, et al. Global distribution of treatment resistance gene markers for leishmaniasis. J Clin Lab Anal. 2022 Aug;36(8):e24599. DOI:10.1002/jcla.24599. Epub 2022 Jul 9. PMID: 35808933; PMCID: PMC9396204.
   PubMed Web of Science ®Google Scholar
• Sundar S, Chakravarty J, Agarwal D, et al. Single-Dose Liposomal Amphotericin B for Visceral Leishmaniasis in India. New Engl J Med. 2010 Feb 11;362(6):504–512.
   PubMed Web of Science ®Google Scholar
• Ouellette M, Drummelsmith J, Papadopoulou B. Leishmaniasis: drugs in the clinic, resistance and new developments. Drug Resist Update. 2004 Aug;7(4–5):257–266.
   PubMed Web of Science ®Google Scholar
• Torrado JJ, Espada R, Ballesteros MP, et al. Amphotericin B formulations and drug targeting. J Pharm Sci-Us. 2008 Jul;97(7):2405–2425.
   PubMed Web of Science ®Google Scholar
• Bagnis CI, Deray G. Amphotericin B nephrotoxicity. Saudi J Kidney Dis Transpl. 2002 Oct;13(4):481–491.
   PubMedGoogle Scholar
• Purkait B, Kumar A, Nandi N, et al. Mechanism of Amphotericin B Resistance in Clinical Isolates of Leishmania donovani. Antimicrob Agents Ch. 2012 Feb;56(2):1031–1041.
   PubMed Web of Science ®Google Scholar
• Verma NK, Dey CS. Possible mechanism of miltefosine-mediated death of Leishmania donovani. Antimicrob Agents Ch. 2004 Aug;48(8):3010–3015.
   PubMed Web of Science ®Google Scholar
• Rakotomanga M, Saint-Pierre-Chazalet M, Loiseau PM. Alteration of fatty acid and sterol metabolism in miltefosine-resistant Leishmania donovani promastigotes and consequences for drug-membrane interactions. Antimicrob Agents Ch. 2005 Jul;49(7):2677–2686.
   PubMed Web of Science ®Google Scholar
• Maarouf M, Lawrence F, Brown S, et al. Biochemical alterations in paromomycin-treated Leishmania donovani promastigotes. Parasitol Res. 1997 Feb;83(2):198–202.
   PubMed Web of Science ®Google Scholar
• Diro E, Ritmeijer K, Boelaert M, et al. Long-term clinical outcomes in visceral leishmaniasis/human immunodeficiency virus-coinfected patients during and after pentamidine secondary prophylaxis in Ethiopia: a single-arm clinical trial. Clin Infect Dis. 2018 Feb 1;66(3):444–451.
   PubMed Web of Science ®Google Scholar
• Van Bocxlaer K, Caridha D, Black C, et al. Novel benzoxaborole, nitroimidazole and aminopyrazoles with activity against experimental cutaneous leishmaniasis. Int J Parasitol-Drug. 2019 Dec;11:129–138.
   PubMed Web of Science ®Google Scholar
• Calvo-Alvarez E, Stamatakis K, Punzon C, et al. Infrared fluorescent imaging as a potent tool for in vitro, ex vivo and in vivo models of visceral leishmaniasis. PLoS Neglect Trop D. 2015 Mar;9(3):e0003666. DOI:10.1371/journal.pntd.0003666. PMID: 25826250; PMCID: PMC4380447.
   PubMed Web of Science ®Google Scholar
• Wyllie S, Thomas M, Patterson S, et al. Cyclin-dependent kinase 12 is a drug target for visceral leishmaniasis. Nature. 2018 Aug 9;560(7717):192±.
   PubMed Web of Science ®Google Scholar
• Garcia AR, Oliveira DMP, Amaral ACF, et al. Leishmania infantum arginase: biochemical characterization and inhibition by naturally occurring phenolic substances. J Enzym Inhib Med Ch. 2019 Jan 1;34(1):1100–1109.
   PubMed Web of Science ®Google Scholar
• Nocentini A, Osman SM, Almeida IA, et al. Appraisal of anti-protozoan activity of nitroaromatic benzenesulfonamides inhibiting carbonic anhydrases from Trypanosoma cruzi and Leishmania donovani. J Enzym Inhib Med Ch. 2019 Jan 1;34(1):1164–1171.
   PubMed Web of Science ®Google Scholar
• Ceruso M, Carta F, Osman SM, et al. Inhibition studies of bacterial, fungal and protozoan beta-class carbonic anhydrases with Schiff bases incorporating sulfonamide moieties. Bioorgan Med Chem. 2015 Aug 1;23(15):4181–4187.
   PubMed Web of Science ®Google Scholar
• Vermelho AB, Capaci GR, Rodrigues IA, et al. Carbonic anhydrases from Trypanosoma and Leishmania as anti-protozoan drug targets. Bioorgan Med Chem. 2017 Mar 1;25(5):1543–1555.
   PubMed Web of Science ®Google Scholar
• Debnath A. Drug discovery for primary amebic meningoencephalitis: from screen to identification of leads. Expert Rev Anti-Infe. 2021 Sep 2;19(9):1099–1106.
   PubMed Web of Science ®Google Scholar
• Kofman A, Guarner J. Infections caused by free-living amoebae. J Clin Microbiol. 2022 Jan 19;60(1):e0022821.
   PubMed Web of Science ®Google Scholar
• Vannier E, Jr C JJ, inventors COMPOSITIONS and METHODS for the PROPHYLAXIS and TREATMENT of BABESIOSIS. US2022409713.
   Google Scholar
• LI X, WANG J, LI Y, et al. Application of cinnefungin in preparation of medicine for preventing or treating babesia disease. https://patents.google.com/patent/CN115177628A/en?oq=LI+X%2c+WANG+J%2c+LI+Y%2c+et+al.+Application+of+cinnefungin+in+preparation+of+medicine+for+preventing+or+treating+babesia+disease.+CN115177628
   Google Scholar
• Y PAN, ZHANG J, QU W, et al. Quinoxaline-N1, N4-dioxide derivatives. CN114621195.
   Google Scholar
• Avila-Bonilla RG, Velazquez-Guzman JA, Reyes-Zepeda EI, et al. Comparative genomics and interactomics of polyadenylation factors for the prediction of new parasite targets: entamoeba histolytica as a working model. Biosci Rep. 2023 Feb 27;43(2):BSR20221911. DOI:10.1042/BSR20221911. PMID: 36651565; PMCID: PMC9912109.
   PubMed Web of Science ®Google Scholar
• Marchat LA, Ospina Villa JD. Aptameros with amebicide activity and their use as biomarkers. https://patents.google.com/patent/MX2019002502A/en?oq=+Marchat+LA%2c+Ospina+Villa+JD.+Aptameros+with+amebicide+activity+and+their+use+as+biomarkers.+MX2019002502
   Google Scholar
• R SG, Ángeles OT. NOVEL AMOEBICIDAL COMPOUNDS DERIVED from ETHYL and METHYL QUINOXALINE-7-CARBOXYLATE. MX2014006538. https://patents.google.com/patent/MX2014006538A/en?q=(NOVEL+AMOEBICIDAL+COMPOUNDS+DERIVED+from+ETHYL+METHYL+QUINOXALINE-7-CARBOXYLATE)&oq=NOVEL+AMOEBICIDAL+COMPOUNDS+DERIVED+from+ETHYL+and+METHYL+QUINOXALINE-7-CARBOXYLATE
   Google Scholar
• world-malaria-report. 2022 Available from. https://www.who.int/teams/global-malaria-programme/reports/world-malaria-report-2022
   Google Scholar
• Supuran CT. Coronaviruses. Expert Opin Ther Pat. 2021 Apr;31(4):291–294.
   PubMed Web of Science ®Google Scholar
• Mori M, Capasso C, Carta F, et al. A deadly spillover: sARS-CoV-2 outbreak. Expert Opin Ther Pat. 2020 Jul;30(7):481–485.
   PubMed Web of Science ®Google Scholar